J Rheumatol 2014;91;1-85
http://www.jrheum.org/content/91.citation

1. Sign up for TOCs and other alerts
http://www.jrheum.org/alerts

2. Information on Subscriptions
http://jrheum.com/faq

3. Information on permissions/orders of reprints
http://jrheum.com/reprints_permissions

The Journal of Rheumatology is a monthly international serial edited by Earl D. Silverman featuring research articles on clinical subjects from scientists working in rheumatology and related fields.
Biologics and Tuberculosis Risk: The Rise and Fall of an Old Disease and Its New Resurgence

Introduction  Biologics and Tuberculosis Risk: The Rise and Fall of an Old Disease and Its New Resurgence
F. Cantini, D. Goletti ................................................................. 1

Update on the Epidemiology of Tuberculosis in Italy
M. Conversano ................................................................. 4

The Spectrum of Tuberculosis Infection: New Perspectives in the Era of Biologics
G. Delogu, D. Goletti ................................................................. 11

Cellular and Humoral Immune Responses During Tuberculosis Infection:
Useful Knowledge in the Era of Biological Agents
A. Matucci, E. Maggi, A. Vultaggio ..................................................... 17

Performance of the Tuberculin Skin Test and Interferon-γ Release Assays: An Update on the Accuracy, Cutoff Stratification, and New Potential Immune-based Approaches
D. Goletti, A. Sanduzzi, G. Delogu ..................................................... 24

Diagnostic Accuracy of Chest Radiography for the Diagnosis of Tuberculosis (TB) and Its Role in the Detection of Latent TB Infection: a Systematic Review
R. Piccazzo, F. Paparo, G. Garlaschi ..................................................... 32

Diagnosis of Latent Tuberculosis and Prevention of Reactivation in Rheumatic Patients Receiving Biologic Therapy: International Recommendations
F. Iannone, F. Cantini, G. Lapadula ..................................................... 41

Adalimumab, Etanercept, Infliximab, and the Risk of Tuberculosis: Data from Clinical Trials, National Registries, and Postmarketing Surveillance
F. Cantini, L. Niccoli, D. Goletti ..................................................... 47

Tuberculosis Risk in Patients Treated with Non-Anti-Tumor Necrosis Factor-α (TNF-α) Targeted Biologics and Recently Licensed TNF-α Inhibitors: Data from Clinical Trials and National Registries
F. Cantini, L. Niccoli, D. Goletti ..................................................... 56

Tuberculosis Reactivation Risk in Dermatology
L. Pescitelli, F. Ricceri, F. Prignano ..................................................... 65

Current Treatment Options for Latent Tuberculosis Infection
M. Bocchino, A. Matarese, A. Sanduzzi ..................................................... 71

Restarting Biologics and Management of Patients with Flares of Inflammatory Rheumatic Disorders or Psoriasis During Active Tuberculosis Treatment
F. Cantini, F. Prignano, D. Goletti ..................................................... 78

Cost for Tuberculosis Care in Developed Countries: Which Data for an Economic Evaluation?
L. Trieste, G. Turchetti ..................................................... 83